Give back to your high performer with
NexHA™ (hyaluronate sodium) Injectable Solution.
NexHA™ (hyaluronate sodium) Injectable Solution is FDA approved as bioequivalent to Legend® intravenous injection at an affordable price.
Using affordable generics allows owners to invest in other important veterinary services.
NexHA is approved for the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.
In a study, overall clinical improvement was judged as excellent or good in 90% of the cases treated intravenously.2
In one study, lameness improved for about six weeks after intravenous administration of sodium hyaluronate.3
Treatment with NexHA may be repeated at weekly intervals for a total of three treatments. The product is available in a 4 mL (40 mg) vial size for intravenous injection. NexHA can be used with other joint therapies.
NexHA is made by extracting hyaluronic acid from the capsule of Streptococcus spp., which is then purified, resulting in a form that is essentially free of protein and nucleic acids. The hyaluronic acid produced by bacteria is the same structure and configuration as found in mammals.2
NexHA is pyrogen free, sterile, and does not contain a preservative.
Hyaluronic acid is a naturally occurring substance present in the connective tissue in all mammals.2
It is found in many tissues and fluids, but more abundantly in articular cartilage and synovial fluid.4
Hyaluronate sodium exerts an anti-inflammatory action, which can help calm synovial inflammation associated with equine osteoarthritis.2 Hyaluronic acid also provides lubrication of joints.4
Veterinarians can request NexHA from their Vetoquinol Territory Manager or preferred distributor representative. NexHA is a prescription-only product.
Important Safety Information
NexHA™ (hyaluronate sodium) Injectable Solution is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.
IMPORTANT SAFETY INFORMATION:
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For use only in horses. Do not use in horses intended for human consumption.
NexHA™ (hyaluronate sodium) Injectable Solution 4 mL is approved only for I.V. use.
The safety of NexHA™ (hyaluronate sodium) Injectable Solution has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares. Not for use in humans. Keep this and all other drugs out of reach of children. Post-Approval Experience: While all adverse reactions are not reported, the following adverse reactions are based on voluntary post-approval reporting for hyaluronate sodium injectable solution: Occasional depression, lethargy and fever. For full prescribing information, visit www.vetoquinolusa.com/nexha-info.
REFERENCES: